14 Nov Repositioning Bazedoxifene For Use Against Pancreatic Cancer

Dr. Lin

MedicalResearch.com Interview with:
Jiayuh Lin, Ph.D.
Associate Professor,
College of Medicine,
The Ohio State University

Medical Research: What is the background for this study? What are the main findings?

Dr. Jiayuh Lin: Pancreatic cancer is one of the most serious forms of cancer.  Because of the poor response to chemotherapy as conventionally used, patients with any stage of pancreatic cancer may appropriately be considered candidates for clinical trials using novel agents.

IL-6 signaling plays an important role in oncogenesis and high serum IL-6 levels is a poor prognostic factor for overall survival in pancreatic cancer. Therefore, IL-6 is considered as a viable target for pancreatic cancer therapy.  We utilized a drug discovery method with Multiple Ligand Simultaneous Docking and drug repositioning to identify an existing FDA-approved drug Bazedoxifene with previously unknown biological function as an IL-6/GP130 inhibitor.  Bazedoxifene can inhibit cell viability of pancreatic cancer cells expressing IL-6 and suppressed pancreatic tumor growth in vivo.

Medical Research: What should clinicians and patients take away from your report?

Dr. Jiayuh Lin: Repositioning a drug such as Bazedoxifene already approved for safety by the FDA as a novel inhibitor of IL-6/GP130 signaling should provide an easier path to clinical trials and may Repositioning a drug such as Bazedoxifene already approved for safety by the FDA as a novel inhibitor of IL-6/GP130 signaling should provide an easier path to clinical trials and may have a potential to enhance the therapy of pancreatic cancer.

Medical Research: What recommendations do you have for future research as a result of this study?

Dr. Jiayuh Lin: Further evaluation of the efficacy of Bazedoxifene in combination of another drugs used in pancreatic cancer therapy such as nab-paclitaxel and gemcitabine in pancreatic tumor animal models should be conducted.

Citation:

upcoming AACR abstract:
Repositioning Bazedoxifene as a novel inhibitor of IL-6/GP130 signaling for pancreatic cancer therapy and

Feedback Activation of STAT3 as a Cancer Drug-Resistance Mechanism

[wysija_form id=”5″]

Jiayuh Lin, Ph.D. (2015). Repositioning Bazedoxifene For Use Against Pancreatic Cancer 

Last Updated on November 14, 2015 by Marie Benz MD FAAD